In cervical cancer, the upregulation of EGR2 may enhance the anti-tumor immune response by promoting the differentiation of T-cells into a more cytotoxic phenotype, which is essential for eliminating cancer cells during therapies such as chemoradiation and immunotherapy. This evidence concerns the gene EGR2 and cervical cancer.